Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook - CNBC
AI Summary1 min read
TL;DR
Pfizer exceeded quarterly sales estimates driven by demand for its non-Covid drugs, despite a decline in Covid-related products. The company reaffirmed its modest outlook for 2026, though its stock fell due to concerns over future growth.
Tags
Pfizerquarterly earningsCovid product declinestock performance2026 guidance
- Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook CNBC
- Pfizer Beats Sales Estimates on Demand for Older Drugs Bloomberg
- Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand The Wall Street Journal
- Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street. Barron's
- Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance Yahoo Finance